Picture loading failed.

Anti-TNFRSF4 therapeutic antibody (Pre-made Vonlerolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Vonlerolizumab (MOXR 0916), a monoclonal antibody targeting the OX40 ligand, was being developed by Genentech as an intravenously administered treatment for solid tumours.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-628-1mg 1mg 3090
GMP-Bios-ab-628-10mg 10mg 21890
GMP-Bios-ab-628-100mg 100mg 148000
GMP-Bios-ab-628-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFRSF4 therapeutic antibody (Pre-made Vonlerolizumab biosimilar,Whole mAb)
INN Name Vonlerolizumab
TargetTNFRSF4
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure6okn:AB:CB/6ogx:CD
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2017
CompaniesGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours;Urogenital cancer
Development Techna